USPTO 2015–2025 USPTO PatentsView US Corporation

Oncosec Medical Incorporated

USPTO PatentsView assignee record - 8 granted patents across 12 technology areas, active 2015–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

16.8

Avg claims per patent

+67%

5-year filing velocity

The verdict

Oncosec holds 8 US patents across 12 technology areas, rank #32,744 of 50,000 tracked assignees.

#32,744
of 50,000 US assignees by volume: Top 46%
by Innovation Score (36.5/100): 16.8
avg claims per patent: +67%
filing velocity, last 5 yrs

Portfolio overview

Oncosec Medical Incorporated has been granted 8 US utility patents between 2015 and 2023, placing Oncosec Medical Incorporated at rank #32,744 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.8 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Oncosec Medical Incorporated is one of the more focused assignees in the PatentsView dataset. By volume, Oncosec sits between Omnicharge, Inc. (8 patents, rank #32,740) and Opal Labs Inc. (8 patents, rank #32,748) - the closest US assignees by grant volume. The composite Innovation Score of 36.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 3 in the 2015–2019 window, a +67% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Oncosec Medical Incorporated's 16.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Oncosec Medical Incorporated against peers pursuing similar technology classes.

Omnicharge

8
Omnis Advanced

8
Onboard Security

8
Oncam Global

8
Onduline

8
Oneblade

8
Onward Multi-

8
Opal Labs

8
Oncosec Medical I… ◀

8

What this shows Oncosec holds 8 patents at rank #32,744, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Oncosec

By rank, the assignees closest to #32,744 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Oncosec's primary technology class.

Oncosec's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

37 Top 46% higher than 54% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Oncosec Medical Incorporated patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	25.0%
2019	1	12.5%
2021	2	25.0%
2022	1	12.5%
2023	2	25.0%

Which technologies does Oncosec Medical Incorporated patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 7

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 5

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 5

C07K - PEPTIDES 3

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 3

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

C12M - APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS 1

H02H - EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS 1

H03K - PULSE TECHNIQUE 1

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 1

Top 12 of 12 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#32,744

Across all tracked assignees

Innovation Score

36.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Oncosec Medical Incorporated hold?

Oncosec Medical Incorporated holds 8 US granted patents filed between 2015 and 2023, spanning 12 technology areas.

What is Oncosec Medical Incorporated's Innovation Score?

Oncosec Medical Incorporated has an Innovation Score of 36.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Oncosec Medical Incorporated focus on?

Oncosec Medical Incorporated's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 7 patents. The company has filed patents in 12 CPC subclasses total.

Is Oncosec Medical Incorporated's patent filing rate increasing or decreasing?

Oncosec Medical Incorporated's recent filing velocity is +67% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Oncosec Medical Incorporated's patents?

Oncosec Medical Incorporated's patents average 16.8 claims each. This falls within the standard range, providing solid legal coverage.

How is the Oncosec Medical Incorporated patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Oncosec's 8 grants land it in the top 46% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Oncosec ranks #32,744 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.